Of mitochondrion and COVID-19. (1st January 2021)

• Record Type: Journal Article
• Authors: Alfarouk, Khalid Omer; Alhoufie, Sari T. S.; Hifny, Abdelhameed; Schwartz, Laurent; Alqahtani, Ali S.; Ahmed, Samrein B. M.; Alqahtani, Ali M.; Alqahtani, Saad S.; Muddathir, Abdel Khalig; Ali, Heyam; Bashir, Adil H. H.; Ibrahim, Muntaser E.; Greco, Maria Raffaella; Cardone, Rosa A.; Harguindey, Salvador; Reshkin, Stephan Joel
• Is Part Of: Journal of enzyme inhibition and medicinal chemistry. Volume 36:Number 1(2021)
• Page Start: 1258
• Page End: 1266
• Publication Date: 2021-01-01
• Subjects: COVID-19 -- mitochondrion -- inflammation -- cytokine storm -- treatment; Enzyme inhibitors -- Periodicals; Enzyme Inhibitors -- periodicals; Biochemistry -- periodicals; 572.7
• DOI: 10.1080/14756366.2021.1937144
• Languages: English
• ISSNs: 1475-6366

Abstract

Abstract: COVID-19, a pandemic disease caused by a viral infection, is associated with a high mortality rate. Most of the signs and symptoms, e.g. cytokine storm, electrolytes imbalances, thromboembolism, etc., are related to mitochondrial dysfunction. Therefore, targeting mitochondrion will represent a more rational treatment of COVID-19. The current work outlines how COVID-19's signs and symptoms are related to the mitochondrion. Proper understanding of the underlying causes might enhance the opportunity to treat COVID-19.